Clinical trials: Mycobacterium Infection
HIV, Tuberculosis
Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)
The purpose of this study is twofold: (1) to assess the feasibility and safety of fixed dose combination zidovudine/lamivudine/abacavir in HIV infected subjects with tuberculosis in a resource-limited setting, and (2) to assess…
- Trial name
- THIRST (NCT00851630)
- Testing
- Fixed dose combination zidovudine/lamivudine/abacavir
- Where
- Tanzania
- Volunteers
- 70 people
- Sponsor
- Duke University
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Tuberculosis
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route
This is a phase I study that will compare the safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route in healthy adult individuals who have been…
- Trial name
- NCT01181856
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Latent Tuberculosis
Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts
To evaluate CT abnormalities in the lung parenchyma in close contacts at high risk for developing multidrug- or extensively drug-resistant Tb by using a follow-up ultralow dose CT scan.
- Trial name
- NCT02454738
- Testing
- Ultralow dose chest CT scan
- Where
- South Korea
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Adjuvant, Treatment
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis.
- Conditions
- Adjuvant, Treatment, Tuberculosis
- Trial name
- NCT06403943
- Testing
- BaiDiZiYin Pill, ShenQiYiFei Pill, Anti tuberculosis chemotherapy
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis, Latent Tuberculosis
Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers
Tuberculosis is still the most common infectious disease in Taiwan. The infants in Taiwan have been vaccinated at birth with BCG -Tokyo 171 strain since 1951.
- Conditions
- Tuberculosis, Latent Tuberculosis, Tuberculosis Contact, Elderly
- Trial name
- NCT00311220
- Testing
- tuberculin for skin test
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
HIV Infection, HIV-1 Infection
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and…
- Conditions
- HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)
- Trial name
- RIFAMARA (NCT01894776)
- Testing
- Rifabutin, Maraviroc
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Tuberculosis, Pleural
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
Tuberculosis (TB) is one of the major global health threats and is the second leading infectious cause of death after COVID-19 in 2022.
- Trial name
- MYDNITE-2 (NCT06439810)
- Testing
- Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)
- Where
- Hong Kong
- Volunteers
- 400 people
- Sponsor
- Chinese University of Hong Kong
Tuberculosis, Covid19
Impact of the Respiratory Isolation on the Quality of Life in Patients Hospitalized for Tuberculosis or COVID-19
The respiratory isolation could have a harmful impact on the well-being of patients, especially in a psychological point of view such as anxiety and depression disorders or through the relationship with medical team and/or…
- Trial name
- ISO-BK (NCT04677478)
- Testing
- Impact of respiratory isolation on quality of life
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mycobacterium Avium-intracellulare Infection, HIV Infections
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the…
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Trial name
- NCT00000933
- Where
- 15 sites in United States
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Psoriasis Vulgaris, Tuberculosis
Frequency of Tuberculosis in Psoriasis Patients
Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.
- Trial name
- NCT06563635
- Where
- Turkey (Türkiye)
- Volunteers
- 719 people
- Sponsor
- Bezmialem Vakif University
Lung Cancer, Lung Tuberculosis
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT
Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.
- Trial name
- NCT02481726
- Testing
- 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Latent Tuberculosis, Active Tuberculosis
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
Tuberculosis (TB) control remains a public health challenge. Many people in the UK do not have a general practitioner (GP) registration and their only interaction with the NHS is via Accident and Emergency (A\&E) Departments of…
- Trial name
- ACE (NCT02512484)
- Testing
- venepuncture, sputum collection, xray
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Public Health England
Tuberculosis, HIV
Arginine as an Adjuvant Treatment Against Tuberculosis
The purpose of this study was to investigate if adjuvant treatment with arginine (the substrate for nitric oxide production) rich food supplements could improve clinical outcome in patients with smear positive tuberculosis by…
- Trial name
- NCT00857402
- Testing
- Peanuts, Daboqolo
- Where
- Ethiopia
- Volunteers
- 180 people
- Sponsor
- Linkoeping University
Spondyloarthritis
Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh
Treatment failure of Spondyloarthropathies (SpA) leads to marked functional disability, higher rates of morbidity, mortality and poor quality of life.
- Trial name
- NCT03504072
- Testing
- Tofacitinib 5 mg,, Etanercept
- Where
- Bangladesh
- Volunteers
- 174 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
PRACTECAL-PKPD Sub Study
PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the TB-PRACTECAL trial investigational regimens and…
- Conditions
- Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculosis
- Trial name
- PRACTECAL-PKPD (NCT04081077)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 5 sites in Belarus, South Africa
- Volunteers
- 240 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Pneumonia, Tuberculosis, Pulmonary
The LalelaLung Study: Digital Stethoscope Clinical Evaluation
Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries.
- Conditions
- Pneumonia, Tuberculosis, Pulmonary, Respiratory Tract Infections, Bronchiolitis
- Trial name
- LaLeLa (NCT07631377)
- Testing
- StethoMe AI-enabled digital stethoscope system, Standard IMCI assessment
- Volunteers
- 350 people
- Sponsor
- Johns Hopkins University
Tuberculosis
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or…
- Trial name
- NCT05382312
- Testing
- GSK3036656, Bedaquiline, Delamanid
- Where
- South Africa
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Tuberculosis, Drug Induced Liver Injury
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).
- Conditions
- Tuberculosis, Drug Induced Liver Injury, Hepatitis
- Trial name
- NCT05738681
- Testing
- N acetyl cysteine
- Where
- Thailand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Tuberculosis
Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings
Each year, 10.4 million patients are diagnosed with and 1.8 million people die from Tuberculosis (TB). Despite the availability of highly effective and accessible medications in the developing world where TB is endemic, the 6-18…
- Trial name
- NCT03135366
- Testing
- Keheala, Standard of Care
- Volunteers
- 1,190 people
- Sponsor
- Yale University